Huh? NICE sets a cost-effectiveness threshold of about £20,000-30,000 per QALY gained from a drug[0]. There was even a controversy where a drug for pancreatic cancer was denied funding for this very reason[1].

[0]https://web.archive.org/web/20110925050527/http://www.nice.o...

[1]https://web.archive.org/web/20151225115559/http://www.pancre...